{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:09:12Z","timestamp":1759410552592},"reference-count":32,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.vaccine.2015.08.019","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T05:17:36Z","timestamp":1439961456000},"page":"5110-5117","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical testing of pre-pandemic live attenuated A\/H5N2 influenza candidate vaccine in adult volunteers: Results from a placebo-controlled, randomized double-blind phase I study"],"prefix":"10.1016","volume":"33","author":[{"given":"Larisa","family":"Rudenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Kiseleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Stukova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Erofeeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoly","family":"Naykhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Donina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Larionova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pisareva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Krivitskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2015.08.019_bib0165","doi-asserted-by":"crossref","first-page":"539","DOI":"10.20506\/rst.33.2.2289","article-title":"Animal and human influenzas","volume":"33","author":"Peiris","year":"2014","journal-title":"Rev Sci Technol"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.virusres.2013.07.017","article-title":"Transmission of influenza A\/H5N1 viruses in mammals","volume":"178","author":"Imai","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0175","unstructured":"Development of a clinical trial plan for pandemic influenza vaccines. National Institute of Allergy and Infectious Diseases. Meeting Summary. September 22\u201323, 2003. Bethesda, Maryland. Available at \u3008http:\/\/www.niaid.nih.gov\/about\/organization\/dmid\/Documents\/pansummary.pdf\u3009 (accessed 21 September 2014)."},{"key":"10.1016\/j.vaccine.2015.08.019_bib0180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1750-2659.2012.00350.x","article-title":"An open-label Phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults","volume":"7","author":"Talaat","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0185","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.vaccine.2009.05.099","article-title":"Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults","volume":"27","author":"Karron","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0190","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1016\/j.vaccine.2011.02.043","article-title":"An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults","volume":"29","author":"Talaat","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0195","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1016\/j.vaccine.2009.03.082","article-title":"A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults","volume":"27","author":"Talaat","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/596558","article-title":"A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults","volume":"199","author":"Karron","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0205","series-title":"Global pandemic influenza action plan to increase vaccine supply","author":"WHO","year":"2006"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.08.019_bib0210","doi-asserted-by":"crossref","first-page":"A40","DOI":"10.1016\/j.vaccine.2011.04.122","article-title":"Live attenuated pandemic influenza vaccine: clinical studies on A\/17\/California\/2009\/38 (H1N1) and licensing of the Russian\u2014developed technology to WHO for pandemic influenza preparedness in developing countries","volume":"29","author":"Rudenko","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0215","series-title":"Proceedings of the international conference on options for the control of influenza VI","first-page":"591","article-title":"Development of candidate H7N3 live attenuated cold-adapted influenza vaccine","author":"Desheva","year":"2007"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0220","first-page":"208","article-title":"Live attenuated influenza vaccines against highly pathogenic H5N1 avian influenza: development and preclinical characterization","volume":"4","author":"Larionova","year":"2013","journal-title":"J Vaccines Vaccin"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0225","doi-asserted-by":"crossref","first-page":"e87962","DOI":"10.1371\/journal.pone.0087962","article-title":"Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized, double-blind phase 1 study of live attenuated H7N3 influenza vaccine","volume":"9","author":"Rudenko","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0230","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.1016\/j.vaccine.2006.06.023","article-title":"Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential","volume":"24","author":"Desheva","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0235","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1016\/j.vaccine.2006.05.039","article-title":"Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses","volume":"24","author":"Lu","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0240","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1750-2659.2008.00064.x","article-title":"Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I\u2013II clinical trials)","volume":"2","author":"Rudenko","year":"2008","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0245","unstructured":"Gelfand AS, Bryzgalova SI, Melnikov SJ. A method of producing live influenza vaccine for the prevention of influenza. 2006. Patent RU 2290205 [Russian]. Available at \u3008http:\/\/www.findpatent.ru\/patent\/229\/2290205.html\u3009.(accessed 14 March 2015)."},{"key":"10.1016\/j.vaccine.2015.08.019_bib0250","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1099\/vir.0.017996-0","article-title":"PB2 and PA genes control the expression of the temperature-sensitive phenotype of cold-adapted B\/USSR\/60\/69 influenza master donor virus","volume":"91","author":"Kiseleva","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0255","series-title":"Manual on animal influenza diagnosis and surveillance","author":"WHO","year":"2002"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0260","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0265","series-title":"Global influenza preparedness plan","author":"WHO","year":"2005"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0270","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/infdis\/jiu123","article-title":"A live attenuated H5N1 vaccine induces long-term immunity in the absence of a primary antibody response","volume":"209","author":"Talaat","year":"2014","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2015.08.019_bib0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virusres.2013.05.006","article-title":"H5N1 vaccines in humans","volume":"178","author":"Baz","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0280","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1371\/journal.pmed.0030360","article-title":"Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets","volume":"3","author":"Suguitan","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0285","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.humimm.2011.03.001","article-title":"Comparison of antibody and T-cell responses elicited by licensed inactivated-and live-attenuated influenza vaccines against H3N2 hemagglutinin","volume":"72","author":"Basha","year":"2011","journal-title":"Hum Immunol"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0290","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jir436","article-title":"Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children","volume":"204","author":"Hoft","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0295","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/infdis\/jis641","article-title":"Localized mucosal response to intranasal live attenuated influenza vaccine in adults","volume":"207","author":"Barria","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0300","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/infdis\/jir596","article-title":"Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets","volume":"204","author":"Gustin","year":"2011","journal-title":"J Infect Dis"},{"issue":"42","key":"10.1016\/j.vaccine.2015.08.019_bib0305","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1016\/j.vaccine.2013.08.040","article-title":"H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus","volume":"31","author":"Rudenko","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.08.019_bib0310","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1128\/CVI.00819-13","article-title":"Characterization of reverse genetics-derived cold-adapted master donor virus A\/Leningrad\/134\/17\/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model","volume":"21","author":"Isakova-Sivak","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0315","first-page":"45","article-title":"Efficacy of live attenuated cold-adapted influenza vaccine during the circulation of drift influenza viruses","volume":"1","author":"Grigorieva","year":"2009","journal-title":"Epidemiol Vaccinal Prev"},{"key":"10.1016\/j.vaccine.2015.08.019_bib0320","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Celluar immune correlates of protection against symptomatic pandemic influenza","volume":"10","author":"Sridhar","year":"2013","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15011330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15011330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T09:24:02Z","timestamp":1599470642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15011330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":32,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0264410X15011330"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.08.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical testing of pre-pandemic live attenuated A\/H5N2 influenza candidate vaccine in adult volunteers: Results from a placebo-controlled, randomized double-blind phase I study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}